Statements (38)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
BRAF inhibitor |
| gptkbp:administeredBy |
oral
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA 2018 |
| gptkbp:ATCCode |
L01XE47
|
| gptkbp:brand |
gptkb:Braftovi
|
| gptkbp:CASNumber |
gptkb:1265820-89-2
|
| gptkbp:combines |
gptkb:binimetinib
|
| gptkbp:developedBy |
gptkb:Array_BioPharma
|
| gptkbp:eliminatedIn |
urine
feces |
| gptkbp:halfLife |
6 hours
|
| gptkbp:hasMolecularFormula |
C22H27ClF2N4O4
|
| https://www.w3.org/2000/01/rdf-schema#label |
encorafenib
|
| gptkbp:KEGGID |
D10813
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedAs |
gptkb:Pfizer
|
| gptkbp:mechanismOfAction |
inhibits BRAF V600E mutation
|
| gptkbp:proteinBinding |
86%
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL2364609
gptkb:DB12010 71238364 |
| gptkbp:sideEffect |
nausea
vomiting diarrhea fatigue hair loss rash arthralgia |
| gptkbp:UNII |
6Z5B6HVF6O
|
| gptkbp:usedFor |
colorectal cancer
melanoma |
| gptkbp:bfsParent |
gptkb:Array_BioPharma
gptkb:BRAF gptkb:BRAF_gene |
| gptkbp:bfsLayer |
5
|